Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

MIAMI- April 6, 2026 - Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd. (Nasdaq: ENTX), a clinical-stage biotechnology company focused on the development of oral peptide and protein replacement therapies, in a $10 million private placement led by funds affiliated with private investment firm BVF Partners L.P.

Under the terms of the transaction, which closed April 2, Entera issued and sold an aggregate of 7,827,789 units at a purchase price of $1.2775 per unit, according to the company's press release. Each unit consists of one ordinary share of Entera, or a pre-funded warrant in lieu thereof, and a five-year warrant to purchase one and a half ordinary shares at an exercise price of $1.24 per share, representing an 11.7% premium to the company's recent closing market price.

Gross proceeds from the private placement were approximately $10 million, before deducting offering expenses. If all warrants issued in the financing are exercised for cash, Entera could receive additional proceeds of approximately $14.5 million, resulting in total potential proceeds of approximately $24.5 million.

The Greenberg Traurig team advising Entera was led by Drew M. Altman, co-chair of the Miami Corporate Practice, with Corporate Shareholder Sami B. Ghneim and Law Clerk Elizabeth Ferrie supporting.

Entera disclosed that it intends to use the net proceeds from the private placement, together with its existing cash and cash equivalents, to support activities related to the initiation of its Phase 3 registrational study of EB613 in postmenopausal women with osteoporosis, as well as for working capital and general corporate purposes.